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elimination half-life. But main criterion for immediate 
release dosage form is poor solubility of the drug and its 
immediate action to treat any unwanted defect or disease. 
Hypertension, commonly referred to as “high blood 
pressure,” is a medical condition where the pressure is 
chronically elevated; it is one of the commonly found 
diseases, affecting most of the populations in the world. 
So, treating hypertension effectively is the main criterion 
of this study. For treating hypertension, commonly used 
drugs include ACE inhibitors, alpha blockers, beta blockers, 
calcium channel blocker, diuretics, and combination of any 
of these categories if immediate action is required.
Conventional immediate release drug delivery system is 
based on single or multiple-unit reservoir or matrix system, 
which are designed to provide immediate drug levels in 
INTRODUCTION
Conventional immediate release drug delivery system 
is based on single- or multiple-unit reservoir or matrix 
system, which are designed to provide immediate drug 
levels in a short period of time. Immediate release drug 
delivery is desirable for drugs having long biological 
half-life, high bioavailability, lower clearance, and lower 
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ABSTRACT
The present invention relates to produce multiple unit particle system (MUPS) of stabilized ramipril pellets, 
hydrochlorothiazide, diluents, superdisintegrants, and lubricants which produce better dissolution of the system 
for better bioavailability with improving stability and bioavailability of ramipril. More particularly, the present 
invention is directed for stabilized ramipril against decomposition into degradation products, namely ramipril-
DKP and ramipril-diacid, during formulation and storage conditions. Simple ramipril formulation shows 15.15% 
related impurities after 3-month accelerated stability study, which was minimized to the 2.07% related impurities in 
ramipril pellets after 6 month accelerated stability study. By making MUPS of ramipril pellets, Hydrochlorothiazide 
and other excipients show better dissolution (100.4% of ramipril and 97.9% of hydrochlorothiazide within 60 
min) to produce better bioavailability. So, making MUPS containing ramipril pellets with polymer coating and 
hydrochlorothiazide and other excipients shows better stability of ramipril along degradation and synergistic 
effect among hypertension in immediate delivery.
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short period of time. Immediate release drug delivery is 
desirable for drugs having long biological half-life, high 
bioavailability, lower clearance, and lower elimination half-
life. But main criterion for immediate release dosage form 
is poor solubility of the drug and its immediate action to 
treat any unwanted defect or disease. 
Ramipril is a prodrug and is converted to the active 
metabolite ramiprilat by liver esterase enzymes, and is an 
angiotensin-converting enzyme (ACE) inhibitor, used to 
treat hypertension and congestive heart failure. Its long 
biological half-life (3–16 h), its dose (2.5 mg/day), and 
long elimination phase (9–18 h) suggest its immediate 
action for treating hypertension.[1] Studied combination 
of ramipril with other diuretic provides synergistic 
antihypertensive effect in controlling blood pressure in 
hypertension along with a significant regression of left 
ventricular hypertrophy. Also, hypertensive patients, 
who did not show much response to monotherapy with 
ramipril, showed significant reduction in blood pressure 
when shifted to ramipril-diuretic combination. Among 
all diuretics, hydrochlorothiazide has the low dosage, 
poor solubility, and long half-life to treat hypertension. 
So, combination of ramipril and hydrochlorothiazide 
provides synergistic effects in the treatment of mild to 
moderate hypertension.[2] So, this study focused on the 
development of immediate drug delivery of ramipril and 
hydrochlorothiazide.  Ramipril needs special care when 
formulating into pharmaceutical preparations due to 
the physical stress associated with formulating processes 
which can increase the rate the decomposition of ramipril 
into degradant products. Indeed, factors that influence 
the stability of ramipril formulations are mechanical 
stress, compression, manufacturing processes, excipients, 
storage conditions, heat, and moisture.[3-5] So, the special 
formulation for ramipril is pellets, which gives more stability 
to ramipril from compression and other stress condition 
during formulation and storage conditions. And also pellets 
offer some additional advantages like dispersing freely in 
GI tract, maximizing drug absorption, and minimizing local 
irritation of the drug, which indicates that pellets can be 
used for immediate drug delivery.[6,7]
With regard to the final dosage form, the multiparticulates 
can be filled into hard gelatin capsules or compressed into 
tablets. The compression of multiparticulates into tablets 
is becoming more popular, especially in the USA, where 
hard gelatin capsules have been tampered.[8-10] So, this study 
focused on the development of immediate release tablets 
containing pellets.
MATERIALS AND METHODS
Materials
Ramipril (Hetero labs), hydrochlorothiazide (Unichem 
labs), microcrystalline cellulose (FMC Biopolymer), 
mannitol (Roquette, Signet Chem. Corp), starch (Roquette), 
cross-carmellose sodium (FMC Biopolymer), hydroxy 
propyl methyl cellulose (Shinetsu), talc (Ferro-Belgium), 
magnesium stearate (Ferro-Belgium), colloidal silicone 
dioxide (Degussa).
Preliminary trials
Preliminary study trials were carried out for the formulation 
of ramipril /HCTZ tablets. Literature survey shows that 
ramipril is very sensitive to light moisture, physical or 
chemical stress, and in contact with this ramipril is degrade 
in to the ramipril-diketopiperazine by cyclization or by 
condensation.[11-13] This is tested by doing these preliminary 
trials for tablet formulation. For the stability improvement 
and better formulation of ramipril and hydrochlorothiazide, 
preliminary trials by direct compression method and wet 
granulation method were tried and compacted in to tablets. 
And bilayer technology of both individual drugs was also 
tried for better formulation by compaction method.
Preparation of ramipril pellets by fluidized bed 
processing method
Trial and error method was used for the development of 
formulation of ramipril pellets. With reservoir-type coated 
pellet dosage forms, the polymeric coating must be able to 
withstand the compression force; it can deform but should 
not rupture. Without sufficient elasticity of the film, the 
coating could rupture during compression and the extended 
release properties would be lost. In addition, the bead core 
should also have some degree of plasticity, which can 
accommodate changes in shape and deformation during 
tableting.[14] So, MCC can be used for the core material for 
drug coating. But direct drug coating on MCC will create 
compatibility problem or stress to the ramipril; so, film 
coating on MCC will overcome this problem and give the 
elasticity to the drug as well. Film-coated ramipril pellets 
were prepared by seal coating with hydroxy propyl methyl 
cellulose and then drug coating on same pellets and finally 
film coating was performed on drug-coated pellets.
Seal coating on base materials
Polymer used for seal coating was hydroxy propyl 
methyl cellulose, which is used as film former in 5–15% 
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concentration. So, trial started with 5% concentration of 
polymer for seal coating. And glidant was used in min 
concentration and seal coating was done on MCC as a core 
material.[15] Seal coating on MCC was done by fluid bed 
processor (GLATT machine) using solution of hydroxy 
propyl methyl cellulose in water with talc as a glidant. 
Drug coating on seal-coated pellets
Drug coating was performed on seal-coated pellets along 
with binder hydroxy propyl methyl cellulose. Polymer 
concentration had been taken from 2% to 6% because 
hydroxy propyl methyl cellulose has been used as binder 
in this range of concentration. Here binder was used 
because drug particles can stick to the seal-coated pellets 
and make a uniform drug coating on seal-coated pellets and 
appropriate amount of drug to be contained in selected 
quantity of pellets. Drug coating on seal-coated pellets was 
done by the solution of ramipril in solvent with binder in 
fluid bed processor.
Film coating on drug-coated pellets
Film coating on drug-coated pellets was varied by 
different concentration of hydroxy propyl methyl cellulose 
polymer used as a film former. For film coating, polymer 
concentration taken is in the range of 5–15%. Theoretically 
amount of polymer required for film coating is higher than 
seal coating. So, for film coating, polymer concentration 
taken was in the range of 5–15%. Talc was added for 
reducing the static charge into pellets. By adding talc into 
spraying solution, it helps evaporate during spraying, stick 
to the pellets, and remove the static charge of pellets during 
spraying and drying.[16] 
Tableting of coated pellets with hydrochlorothiazide 
and other excipients
Ramipril/hydrochlorothiazide tablets were done by using 
different concentration of and different proportion of 
diluents. Disintegrating agent like sodium starch glycolate 
(SSG) was used  in different concentration in tablet 
formulation. The usual concentration of SSG employed in 
a formulation is between 2% and 8%,[17,18] with the optimum 
concentration of about 4%, although in many cases 2% is 
sufficient.[19-21] All disintegrating agents are water insoluble. 
Disintegrant is added to the formulations to facilitate 
breakup of the tablet when in contact with water in the GI 
tract. They may function by drawing water into the tablet 
and swelling causing it to burst apart.[22,23]
Diluents like MCC and mannitol were used for formulation 
development. Because, tableting of pellets with diluents 
produce breakage or rupture of pellets and that will affect 
the dissolution profile and stability of tablet. This problem 
is solved by using different granular MCC grade, which 
are available with greater plasticity.[24,25] So, granular grade 
of MCC and mannitol were used for the trial of tablets. 
Evaluation properties of pellets[26-28]
Particle size distribution study of pellets was performed 
by sieving analysis using a nest of standard sieves and the 
desirable range of pellets was taken to be between 450 
and 1180 mm. The post-compaction tests of pellets were 
performed; they included assay, in-vitro dissolution study 
in 0.1 N HCl at specified time interval, and measuring the 
concentration release in time profile by HPLC. Ramipril 
pellets were subjected to the accelerated stability studies 
in aluminum/aluminum pouch. As the dosage form is 
formulated to deliver it into stomach, no change should 
occur in its % dissolution profile and related impurities. 
Ramipril is very sensitive to light, moisture, and any physical 
or chemical stress. For this study, tablets prepared from 
pellets and only pellets were packed in aluminum pouch and 
in vial, respectively, charged for accelerated stability study 
at 40°C and 75% RH for 3 months in a chamber. Stability 
study of pellets was performed by first checking the initial 
parameters of pellets and then put it in specified condition 
for 1 month. After 1 month, check for all parameters. If it 
shows satisfactory results, then continue the test for next 
month and continue for 3 months.
Evaluation properties of tablets
The post-compaction tests were performed on the tablets 
at least 24 h following preparation and they included 
the determination of weight, thickness, drug content 
uniformity, friability (Erweka friabilator, Germany), 
hardness (tablet hardness tester, Schleuniger Pharmaton 6D 
Model, USA), disintegration (Erweka ZT 44, Germany), 
and dissolution testing in 0.1 N HCl, for formulations 
containing coated pellets.[29-31] All tests were performed on 
at least five replicates. The degree of damage to drug pellets 
was assessed by the use of the similarity factor…
F2 = 50 * log {[1 + (1/n) ∑ t=1 
n (R t – Tt) 2] - 0.5 * 100},
where Rt and Tt are the percent dissolved at each time point 
for reference (R) and test (T) products. An F2 value between 
50±100 suggests that the two dissolution profiles are similar 
and the mean dissolution profiles are assumed to differ 
by no more than 15% at any time point.[32] An accelerated 
stability study was also performed in aluminum/aluminum 
pouch of the tablets.
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RESULTS AND DISCUSSION
Preliminary trials
Literature survey showed that ramipril is very sensitive 
to light moisture, physical, or chemical stress, and in 
contact with this ramipril is degraded into the ramipril-
diketopiperazine by cyclization or condensation. This 
is tested by doing these preliminary trials for tablet 
formulation. In the direct compression flow of the blend 
and parameters of tablets were major problem. Where in 
wet granulation method, parameters are in range but as the 
properties of ramipril, it is degraded and showing stability 
problem [Table 1]. Same problem also can be there in 
bilayer formulation because it was also prepared by stress. 
Also the tablet parameters were not within the range. 
Seal coating on microcrystalline cellulose
By using granular grade of MCC, pellets were in spherical 
shape and properly form. From the comparisons of 
sieving analysis of different concentration showed that 
in 7% polymer film coating, pellets are formed and it is 
very regularly distributed in 60# sieves than other two 
concentrations. Pellets of this batch were not breaking 
easily which showed good film formation than other two 
batches. In 5% film coating, fines of powder were seen to 
be very high than other two batches; the small quantity of 
pellets formation was also seen here than the other two 
batches. The pellets were breaking freely which means the 
film coating was not properly done. In 9% film coating, 
aggregation of pellets was seen and pellets were sticking to 
each other and somewhat slugging observed. So, for next 
experiment of drug coating on polymer-coated pellets will 
be done with 7% polymer seal-coated pellets. Sieve analysis 
data of different batches are shown in Table 2.
Drug coating on seal-coated pellets
Drug coating on the seal-coated pellets with different 
proportion of binder concentration was evaluated. 
Three different concentrations of binder (2%, 4%, 6%) 
were taken for drug coating. But by appearance of all 
three batch pellets, 4% binder concentration pellets were 
seen uniform in shape and size. Sieve analysis study of 
all three batches showed that drug-coated pellets were 
retained highest on 40# sieve 4% binder concentration 
than other two concentrations. And also fines were very 
less observed in 4% binder concentration than 2% binder 
concentration. Aggregation of pellets was also less in 4% 
binder concentration than 2% binder concentration. Assay 
of three different batches was found distributed because of 
different proportion of binder concentration in different 
batches; 2% binder concentration assay was observed less 
and in 6% binder concentration higher than required. But in 
4% binder concentration, assay was nearer to required assay. 
From the P.S.D data and % assay data, it was concluded that 
4% polymer used as a binder shows good drug entrapment 
and particle size of pellets.
Film coating on drug-coated pellets
From the sieve analysis study of pellets [Table 3], batch no. 
P 18 (8%) and P 19 (8.5%) showed good pellets. In 7% and 
7.5% concentration, polymer film coating on pellets was 
observed not proper and also plasticity was not observed in 
pellets. Most of the film-coated pellets have to retain on the 
# 30 and # 40 sieve with minimum fines. This criterion was 
only observed in batch no. P 18 (8%), P 19 (8.5%), and P 
20 (9.0%). But in batch no. P 20 aggregation of pellets was 
observed in little amount and sticking of pellets occurred 
to the each other. So from appearance and sieve analysis 
study, it was concluded that batch no. P 18 (8%) and P 
19 (8.5%) show good pellets in comparisons with other 
batches. % Assay of all batches was acceptable and came 
within the range, except batch P 16. % Assay results of all 
batches showed that all batches contain equivalent amount 
of ramipril within the range. Because of final formulation 
of pellets was tablet, dissolution of pellets was carried out 
by converting it into tablet dosage form. In-vitro dissolution 
data of tablet were compared with the release profile of 
innovator dosage form (marketed). From the dissolution 
data, batch no. P 16 (7%) and P 17 (7.5%) show very fast 
release of ramipril. This may be because of the rupture of 
Table 1: Accelerated stability study data of tablets 
prepared by wet granulation method
Parameters 40°C 75%RH 
1M
30°C 75%RH 
1M
% Assay (ramipril:HCTZ) 93.3/95.5 99.3/96.2
% Related impurities (total impurity) 10.2 6.82
% Dissolution (ramipril:HCTZ) 90.3/90.3 95.1/90.4
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Table 2: Sieve analysis results of different % 
concentrations of polymer
ASTM sieve no. % Weight retained of pellets
5% Polymer 7% Polymer 9% Polymer
20 0 0 0
40 0.32 12.2 21.6
60 53.6 74.9 72.1
80 23.7 6.3 4.1
100 15.2 2.4 0.9
Below 100  7.18 4.2 1.394   Journal of Young Pharmacists Vol 3 / No 2
pellets during compression and this rupture of pellets also 
may cause the stability problem of ramipril. While batch 
no. P 18 (8%) and P 19 (8.5%) show good and comparable 
results with the innovator dosage form. And batch no. P 
20 (9.0%) showed little retardation of release than the 
reference product. So, batch no. P 19 (8.5%) showed good 
release and had greater F2 value than other batches. 
Stability study of 8.5% polymer concentration film-coated 
pellets showed no degradation of ramipril and similar 
dissolution as initial at 40°C and 75% RH condition after 
3 months. So, formulation of batch no. P 19, film-coated 
pellets was taken for the next optimization of tablet dosage 
form.
Tableting of coated pellets
These studies were performed to optimize the concentration 
or amount of diluents used in MCC (Avicel) and mannitol 
(Pearlitol SD 200) to give the plasticity to pellets and prevent 
the rupturing of pellets. In batch no. T1, only the MCC 
(Avicel) was used as a diluent (MCC 100%) and in batch 
no. T2 both diluents were used in equal amount (MCC–
mannitol = 50–50%) and in batch no. T3, only mannitol 
(Pearlitol SD 200 – 100%) and was used as a diluent in 
tablet formulation [Table 4]. All the characteristics of these 
batches are discussed next.
Results of micromeritic properties of blend with 
different ratio of diluents 
The micromeritic properties of different batches, i.e., bulk 
density, tapped density, compressibility index, Hausner 
ratio, and angle of repose, revealed no significant difference 
among the batches. Batch no. T1 shows the good flow, 
compressibility, and other parameters than other two 
batches. Loss on drying was also observed to be in the 
range of 2–3% wt/wt for all batches, which passes the USP 
requirements. Thus, from the micromeritic data it is evident 
that blends of different batches possess comparable 
compressibility and flow properties of all batches prepared 
with MCC and Pearlitol SD 200 [Table 5]. 
Physical characteristics of tablets
The tablets of different batches were prepared at same 
adjustment of machine; after that physical characteristics 
were found to be consistent as in all batches and shown 
in Tables 2, 6, and 5. All characteristics of tablets were 
within the limit, and acceptable and comparable with 
the reference product except the disintegration time and 
friability [Table 7].
In vitro dissolution study
Tablets containing only MCC showed very fast dissolution 
into the medium. Those results were acceptable and also 
comparable with the reference product. Batch T2 showed 
the comparable and expected dissolution of tablets. But 
batch T3 showed delayed release of tablets than reference 
product release. In batch T1, fast release was observed 
because of only MCC also used as a disintegrating agent 
and an increase in the concentration of MCC, it will increase 
disintegration of tablets. In batch T3 only pearlitol SD 200 
was used, which is crystalline, water-soluble diluents, and 
does not have any disintegration property. So, this batch 
showed delayed release due to long time for disintegration 
of tablets. But in batch T2, MCC and pearlitol SD 200 
used in same concentration showed similar results to the 
reference product release. Similarity study of all batches is 
shown in Table 8, which shows that B. No. T3 has F2 value 
less than 50 (43.4% for ramipril and 41.1% for HCTZ) for 
both ramipril and HCTZ release compared with reference 
product release, so this batch was not acceptable. Batch 
no. T1 showed F2 value in the range of 50–100 (69.2% 
for ramipril and 63.1% for HCTZ) for both ramipril and 
HCTZ release, compared with reference product release. 
So, this batch was acceptable. But batch no.T2 had shown 
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Table 3: Sieve analysis and assay and F2 value results of different % concentrations of film formers
ASTM sieve no. % Weight retained of pellets
B. No. P-16 (7% polymer) P-17 (7.5% polymer) P-18 (8% polymer) P-19 (8.5% polymer) P-20 (9% polymer)
20 0.7 0.6 1.8 5.8 10.1
30 42.8 50.8 55.1 66.1 71.8
40 35.8 30.1 30.7 24.3 15.8
60 12.2 7.6 4.8 1.3 1.4
80 2.5 4.1 4.1 0.7 0.2
100 3.3 3.8 2.2 1.1 0
Below 100  2.7 3 1.3 0.7 0.7
% Assay 105.1 103.3 101.8 99.8 98.0
F2 value for dissolution 61.40 66.49 76.62 81.36 60.09Journal of Young Pharmacists Vol 3 / No 2  95
Table 7: Physical characteristics of tablet with different ratio of diluents (B. T1, T2, T3)
Batch code Avg. weight (mg) Hardness (N) Thickness (mm) Friability (% w/w) D.T. (min)
T 1 (100% MCC) 196.7–201.8 64–77 2.92–3.07 0.314 % 0.23 
T 2 (50/50% MCC/mannitol) 197.8–202.1 51–60 3.01–3.19 0.395 % 1.26 
T 3 (100% mannitol) 197.1–200.9 53–60 2.98–3.13 Capping 4.48 
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Figure 1: Dissolution profiling of different percentage concentrations 
of film formers
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Figure 2: Dissolution profiling of different ratio of diluents (B. T1, T2, T3)
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Table 6: Sieve analysis and assay results of different % 
concentrations of binder
ASTM sieve no. % Weight retained of pellets
2% Binder 4% Binder 6% Binder
20 0 0 0.86
30 0.2 2.3 8.94
40 41.7 73.8 71.9
60 32.2 20.4 14.2
80 15.4 1 2.1
100 3.8 0.7 0.8
Below 100  6.7 1.8 1.2
% Assay 94.1 99.6 106.8
Table 4: Accelerated stability study data of different % 
concentrations of film formers
Parameters Initial 40°C 75%RH 3 M
% Assay (ramipril) 99.8 93.4
% Related impurities (total impurity) BLOQ 3.63
% Dissolution (ramipril) 99.8 97.1
Table 5: Micromeritic properties of blend with different 
ratio of diluents (B. T1, T2, T3)
Batch code B.D (g/cc) T.D (g/cc) C.I (%) H.R A.R (φ) % LOD
T 1 (100% 
MCC)
0.64 0.72 12.82 1.15 26.50 2.45
T 2 (50/50%  
MCC/mannitol)
0.63 0.73 13.79 1.16 24.10 2.61
T 3 (100% 
mannitol)
0.61 0.75 18.66 1.23 31.45 2.09
F2 value in the range of 50–100 and also nearer to 100 
(87.0% for ramipril and 88.1% for HCTZ), which showed 
good similarity with reference product release of ramipril 
and HCTZ than batch no. T1. Dissolution profile is given 
in Figures 1 and 2.
Accelerated stability study
Accelerated stability data show that ramipril and 
hydrochlorothiazide drugs were not degraded after 
3 months also. And all impurities were also found in 
acceptable range. After a 3-month accelerated stability 
study, there was no change in the tablet disintegration 
time and water content of the tablets. After 3 months, 
dissolution of tablets was performed and compared it 
with the initial dissolution of tablets. The results were not 
affected much during this 3-month period [Table 9]. 
CONCLUSION 
Formulation development of ramipril pellets for 
improving the stability from stress condition with required 
dissolution of tablets was tried with film coating, which 
showed a decrease in the degradation of the ramipril 96   Journal of Young Pharmacists Vol 3 / No 2
after formulation process. After a 3-month accelerated 
stability study of ramipril, pellets and MUPS have shown 
related impurities of 2.35% and 1.49%, respectively, which 
complied the limit of impurities (NMT 5.0%) required in 
final formulation. 
MUPS prepared with super disintegrating agents showed 
100.3% dissolution of ramipril and 98.8% dissolution of 
hydrochlorothiazide within 45 min. This showed that a 
better dissolution of MUPS was achieved within 45 min.
Whole investigation summarized that MUPS prepared 
by incorporating ramipril pellets and hydrochlorothiazide 
with other excipients showed good stability along with 
degradation of ramipril and immediate action of tablet 
with highest bioavailability of both drugs.
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Table 9: Accelerated stability study data of different 
ratio of diluents
Parameters Initial 40°C 75% RH 
3 M
30°C 75% RH 
3 M
% Assay (ramipril: HCTZ) 100.3/98.8 97.7/97.8 100.2/98.3
% Related impurities (total 
impurity)
BLOQ 2.35 1.49
% Dissolution (ramipril: 
HCTZ) in 45 min
99.7/96.2 97.6/94.7 98.3/95.1
% Water Content 3.89 6.63 6.62
Disintegration time (min) 1–17 1–37 1–29
Table 8: F2 value of tablet with different ratio of 
diluents (B. T1, T2, T3) with comparison to reference
Batch code F2 value with comparison to reference
Ramipril (%) HCTZ (%)
T 1 (100% MCC) 69.2 63.1
T 2 (50/50% MCC/mannitol) 87.0 88.1
T 3 (100% mannitol) 43.4 41.1